A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Prostate cancer has a high propensity to metastasize to bone, which often resists hormone, radiation, and chemotherapies. Because of the reciprocal nature of the prostate cancer and bone stroma interaction, we designed a cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts. The recombinant Ad-OC-E1a was constructed using a noncollagenous bone matrix protein osteocalcin (OC) promoter to drive the viral early E1a gene with restricted replication in cells that express OC transcriptional activity. Unlike Ad-PSE-E1a, Ad-OC-E1a was highly efficient in inhibiting the growth of PSA-producing (LNCaP, C4-2, and ARCaP) and nonproducing (PC-3 and DU145) human prostate cancer cell lines. This virus was also found to effectively inhibit the growth of human osteoblasts and human prostate stromal cells in vitro. Athymic mice bearing s.c. androgen receptor-negative and PSA-negative PC-3 xenografts responded to a single intratumoral administration of 2 x 10(9) plaque-forming unit(s) of Ad-OC-E1a. In SCID/bg mice, intraosseous growth of androgen receptor-positive and PSA-producing C4-2 xenografts responded markedly to i.v. administrations of a single dose of Ad-OC-E1a. One hundred percent of the treated mice responded to this systemic Ad-OC-E1a therapy with a decline of serum PSA to an undetectable level, and 80% of the mice with PSA rebound responded to the second dose of systemic Ad-OC-E1a. Forty percent of the mice were found to be cured by systemic Ad-OC-E1a without subsequent PSA rebound or tumor cells found in the skeleton. This cotargeting strategy shows a broader spectrum and appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.
Matsubara
S
S
Department of Urology, Molecular Urology and Therapeutics Program, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA.
Wada
Y
Y
Gardner
T A
TA
Egawa
M
M
Park
M S
MS
Hsieh
C L
CL
Zhau
H E
HE
Kao
C
C
Kamidono
S
S
Gillenwater
J Y
JY
Chung
L W
LW
D017500:Adenovirus E1A Proteins / Q000235:genetics*; D000260:Adenoviruses, Human / Q000235:genetics / Q000502:physiology; D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics / Q000556:secondary* / Q000628:therapy*; D002455:Cell Division; D015316:Genetic Therapy / Q000379:methods*; D006131:Growth Inhibitors / Q000096:biosynthesis / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology / Q000628:therapy; D015675:Osteocalcin / Q000096:biosynthesis / Q000235:genetics*; D010010:Osteoclasts / Q000473:pathology; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000502:physiology; D011471:Prostatic Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy*; D011944:Receptors, Androgen / Q000502:physiology; D017154:Stromal Cells / Q000473:pathology; D014779:Virus Replication; D023041:Xenograft Model Antitumor Assays
D017500:Adenovirus E1A Proteins; D006131:Growth Inhibitors; D011944:Receptors, Androgen; D015675:Osteocalcin; D017430:Prostate-Specific Antigen